Q1 2022

Filed May 5, 2022 · 10-Q · 35 days after period end · 0001091818-22-000041

Q1 2022 · 10-Q

Revenue—

Net Income

-$132.41K

N/M vs Q1 2021

EPS, diluted—

Operating Cash Flow-$32,941N/M

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	—	—	—	$5.85K
Net Income	-$132.41K	-$145.08K	-$158.04M	-$12.85K
EPS Diluted	—	$0.00	-$10.35	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioforce Nanosciences Holdings, Inc. · CIK 1310488 · Engraved from SEC EDGAR